Profil
Dr. Krisztina M.
Zsebo is a Chairman & Chief Executive Officer at VST-Bio Corp.
and a President at Biovest Consulting, LLC.
Dr. Zsebo was previously employed as an Independent Director by BioCardia, Inc., a President, Chief Executive Officer & Director by VasoRx, Inc., a Chief Executive Officer & Director by Celladon Corp., a Vice President by ALZA Corp., a Chief Executive Officer by Actavalon, Inc., a Manager by Amgen, Inc., an Executive VP-Research & Product Development by Cell Genesys, Inc., a Vice President by Connetics Corp., a Venture Partner by Enterprise Partners Venture Capital, and a Principal by Remedyne Corp.
She also served on the board at CG Oncology, Inc. and Anaborex, Inc. She received her undergraduate degree from the University of Maryland, a graduate degree from Oregon State University and a doctorate degree from the University of California, Berkeley.
Postes actifs de Krisztina Zsebo
| Sociétés | Poste | Début |
|---|---|---|
Biovest Consulting, LLC | President | 01/08/2015 |
VST-Bio Corp.
VST-Bio Corp. BiotechnologyHealth Technology Operates as a biotechnology company that develops antibodies for the treatment of inflammatory and cardiovascular diseases | Directeur Général | - |
Anciens postes connus de Krisztina Zsebo
| Sociétés | Poste | Fin |
|---|---|---|
| BIOCARDIA, INC. | Directeur/Membre du Conseil | 18/10/2023 |
VasoRx, Inc.
VasoRx, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Directeur Général | 01/01/2022 |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Develops molecular therapies for cardiovascular diseases | Directeur Général | 01/06/2015 |
Enterprise Partners Venture Capital
Enterprise Partners Venture Capital Investment ManagersFinance Enterprise partners seeks investment opportunities in companies located in the US, primarily in California and New York and also makes invests in Canada. The firm targets companies operating in the fields of telecommunications, life sciences and enterprise software. The firm provides financing for buyout, seed, early and later stage capital requirements with an initial investment of $0.3 million in seed stage and invests up to $3 - $10 million in follow on investments. They acts as a lead investor and makes co-investments. They also takes a seat on the board of directors. | Corporate Officer/Principal | 31/12/2008 |
Actavalon, Inc.
Actavalon, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for cancer treatment | Directeur Général | - |
Formation de Krisztina Zsebo
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 17 |
|---|---|
ALZA Corp.
ALZA Corp. Pharmaceuticals: MajorHealth Technology Provides and develops pharmaceutical products | Health Technology |
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Develops human disease therapies based on innovative gene modification technologies | Health Technology |
Connetics Corp.
Connetics Corp. BiotechnologyHealth Technology Develops and commercializes dermatology products | Health Technology |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Develops molecular therapies for cardiovascular diseases | Health Technology |
Anaborex, Inc.
Anaborex, Inc. Medical/Nursing ServicesHealth Services Provides clinical research services | Health Services |
Oregon State University
Oregon State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Maryland
University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Enterprise Partners Venture Capital
Enterprise Partners Venture Capital Investment ManagersFinance Enterprise partners seeks investment opportunities in companies located in the US, primarily in California and New York and also makes invests in Canada. The firm targets companies operating in the fields of telecommunications, life sciences and enterprise software. The firm provides financing for buyout, seed, early and later stage capital requirements with an initial investment of $0.3 million in seed stage and invests up to $3 - $10 million in follow on investments. They acts as a lead investor and makes co-investments. They also takes a seat on the board of directors. | Finance |
Remedyne Corp.
Remedyne Corp. Packaged SoftwareTechnology Services Develops software for assets management | Technology Services |
CG Oncology, Inc.
CG Oncology, Inc. BiotechnologyHealth Technology Operates as a late-stage clinical biopharmaceutical company focused on developing and commercializing backbone bladder-sparing therapeutic | Health Technology |
Actavalon, Inc.
Actavalon, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for cancer treatment | Health Technology |
BioCardia, Inc.
BioCardia, Inc. BiotechnologyHealth Technology Develops biotherapeutics for cardiovascular disease | Health Technology |
VasoRx, Inc.
VasoRx, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Biovest Consulting, LLC | |
VST-Bio Corp.
VST-Bio Corp. BiotechnologyHealth Technology Operates as a biotechnology company that develops antibodies for the treatment of inflammatory and cardiovascular diseases | Health Technology |
















